Clinical Trial Update: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial assessing the safety of combining UV1 vaccination with ipilimumab in patients with unresectable or metastatic malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• UV1 vaccination (UV1 vaccine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Ultimovacs ASA | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED